Combination of Venetoclax and Hypomethylating Agents Show Efficacy in AML
February 1st 2021Danielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.